PDCD4 exacerbates myocardial ischemia-reperfusion injury via AKT-mediated apoptosis. 2025

Zhiming Zhang, and Zhihui Yang, and Hangbin Ge, and Chenyang Liu, and Renchenghan Fan, and Chenying Yuan, and Shengban You, and Chenglv Hong
Department of Cardiology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.

Myocardial ischemia-reperfusion (I/R) injury is a critical complication following reperfusion therapy for myocardial infarction. As a marker of I/R injury, apoptosis plays an important role in myocardial ischemia-reperfusion injury. Programmed Cell Death 4 (PDCD4) regulates apoptosis in MI/RI, but the mechanism is not yet fully elucidated. In this study, we demonstrate that PDCD4 expression was significantly upregulated in a myocardial I/R injury model. Genetic deletion of PDCD4 markedly reduced infarct size, serum biomarkers of injury (CK-MB, cTnT, LDH), and apoptosis in vivo. Mechanistically, PDCD4 directly interacts with AKT, inhibiting its phosphorylation by reducing ubiquitination. This suppression of AKT activity decreased BCL-2 levels, promoting mitochondrial apoptosis. Silencing PDCD4 restored AKT phosphorylation, attenuated apoptosis, and alleviated myocardial damage. Our findings establish PDCD4 as a key driver of myocardial I/R injury via AKT-mediated apoptosis and highlight its therapeutic potential.

UI MeSH Term Description Entries

Related Publications

Zhiming Zhang, and Zhihui Yang, and Hangbin Ge, and Chenyang Liu, and Renchenghan Fan, and Chenying Yuan, and Shengban You, and Chenglv Hong
November 2023, Folia morphologica,
Zhiming Zhang, and Zhihui Yang, and Hangbin Ge, and Chenyang Liu, and Renchenghan Fan, and Chenying Yuan, and Shengban You, and Chenglv Hong
June 2018, Shock (Augusta, Ga.),
Zhiming Zhang, and Zhihui Yang, and Hangbin Ge, and Chenyang Liu, and Renchenghan Fan, and Chenying Yuan, and Shengban You, and Chenglv Hong
January 2025, Frontiers in pharmacology,
Zhiming Zhang, and Zhihui Yang, and Hangbin Ge, and Chenyang Liu, and Renchenghan Fan, and Chenying Yuan, and Shengban You, and Chenglv Hong
December 1997, The Annals of thoracic surgery,
Zhiming Zhang, and Zhihui Yang, and Hangbin Ge, and Chenyang Liu, and Renchenghan Fan, and Chenying Yuan, and Shengban You, and Chenglv Hong
November 2019, Journal of the American Heart Association,
Zhiming Zhang, and Zhihui Yang, and Hangbin Ge, and Chenyang Liu, and Renchenghan Fan, and Chenying Yuan, and Shengban You, and Chenglv Hong
January 2022, Oxidative medicine and cellular longevity,
Zhiming Zhang, and Zhihui Yang, and Hangbin Ge, and Chenyang Liu, and Renchenghan Fan, and Chenying Yuan, and Shengban You, and Chenglv Hong
December 2015, Experimental and molecular pathology,
Zhiming Zhang, and Zhihui Yang, and Hangbin Ge, and Chenyang Liu, and Renchenghan Fan, and Chenying Yuan, and Shengban You, and Chenglv Hong
July 2020, European journal of pharmacology,
Zhiming Zhang, and Zhihui Yang, and Hangbin Ge, and Chenyang Liu, and Renchenghan Fan, and Chenying Yuan, and Shengban You, and Chenglv Hong
August 2021, Experimental and therapeutic medicine,
Zhiming Zhang, and Zhihui Yang, and Hangbin Ge, and Chenyang Liu, and Renchenghan Fan, and Chenying Yuan, and Shengban You, and Chenglv Hong
March 2022, Molecular medicine (Cambridge, Mass.),
Copied contents to your clipboard!